References
- Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020; 324(8):782–793. doi:10.1001/jama.2020.12839
- National Institutes of Health. Covid-19 Treatment Guidelines. https://www.covid19treatmentguidelines.nih.gov/whatsnew/
- Halpin DMG, Singh D, Hadfield RM. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective. European Respiratory Journal. 2020; 55(5): 2001009. https://doi.org/10.1183/13993003.01009-2020
- Tobin MJ. Basing respiratory management of COVID-19 on physiological principles. Am J Respir Crit Care Med. 2020;201(11):1319-1320. doi:10.1164/rccm.202004-1076ED
- Nevitt SJ, Jones AP, Howard J. Hydroxyurea (hydroxycarbamide) for sickle cell disease. Cochrane Database of Systematic Review. 2017; 4: CD002202. doi: 10.1002/14651858.CD002202.pun2.
- Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infectious Disease. 2020;20(4):425434. doi:10.1016/S1473-3099(20)30086-4
- Dhont S, Derom E, Van Braeckel E, et al. The pathophysiology of ‘happy’ hypoxemia in COVID-19. Respiratory Research. 2020; 21( 198). https://doi.org/10.1186/s12931-020-01462-5
- Khandros E, Huang P, Peslak SA, et al. Understanding heterogeneity of fetal hemoglobin induction through comparative analysis of F and A erythroblasts. Blood. 2020;135(22):1957-1968. doi:10.1182/blood.2020005058
- Panepinto JA, Brandow AM, Singh A. Secure-SCD Registry. Medical College of Wisconsin. (October 2020) https://covidsicklecell.org/
- Ramachandran P, Perisetti A, Kathirvelu B, et al. Low morbidity and mortality with COVID-19 in sickle cell disease: A single center experience. eJHaem. 2020;1–7. https://doi.org/10.1002/jha2.87